Results seem to encourage the incorporation of baseline demographic and anthropometric parameters, e.g., age and body mass index (BMI), into molecular scores for the prediction of distant recurrence in HR+HER2- breast cancer patients [18–19]. This evidence concerns the gene ERBB2 and breast cancer.